Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress

– Treatment with verekitug led to rapid PD effects which were sustained for up to 24 weeks, supporting evaluation of dosing intervals of once every 12 or 24 weeks in ongoing Phase 2 clinical trials – – PK/PD modeling predicts substantially higher clinical potency of verekitug compared to reported tezepelumab data – WALTHAM, Mass. – […] The post Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress appeared first on Upstream Bio .